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The prefrontal cortex (PFC) is involved in higher brain functions
altered in schizophrenia. Classical antipsychotics modulate cortico-
limbic circuits mainly through subcortical D2 receptor blockade,
whereas second generation (atypical) antipsychotics preferentially
target cortical 5-HT receptors. Anatomical and functional evidence
supports a PFC-based control of the brainstem monoaminergic
nuclei. Using a combination of retrograde tracing experiments and
in situ hybridization we report that a substantial proportion of PFC
pyramidal neurons projecting to the dorsal raphe (DR) and/or
ventral tegmental area (VTA) express 5-HT2A receptors. Cholera-
toxin B application into the DR and the VTA retrogradely labeled
projection neurons in the medial PFC (mPFC) and in orbitofrontal
cortex (OFC). In situ hybridization of 5-HT2A receptor mRNA in the
same tissue sections labeled a large neuronal population in mPFC
and OFC. The percentage of DR-projecting neurons expressing 5-
HT2A receptor mRNA was ~60% in mPFC and ~75% in OFC (n 5 3).
Equivalent values for VTA-projecting neurons were ~55% in both
mPFC and ventral OFC. Thus, 5-HT2A receptor activation/blockade in
PFC may have downstream effects on dopaminergic and seroto-
nergic systems via direct descending pathways. Atypical anti-
psychotics may distally modulate monoaminergic cells through PFC
5-HT2A receptor blockade, presumably decreasing the activity of
neurons receiving direct cortical inputs.
Keywords: antipsychotics, dopamine, pyramidal neurons, schizophrenia,
serotonin receptors
Introduction
The prefrontal cortex (PFC) is critically involved in many
higher brain functions, including cognitive functions and
behavioral control, which are altered in schizophrenic patients
(Lewis and Lieberman 2000; Elvevag and Goldberg 2000;
Weinberger et al. 2001). Autopsy and neuroimaging studies
have revealed the existence of a reduced PFC volume, reduced
layer thickness, tight packing of pyramidal neurons and
reduced neuropil in the brains of schizophrenic patients
(Harrison 1999; Selemon and Goldman-Rakic 1999; Lewis and
Lieberman 2000). Alterations in key neurotransmitters such as
glutamate, GABA, and dopamine (DA) have also been reported
in PFC (Lewis and Lieberman 2000; Benes and Berretta 2001;
Lewis et al. 2005). Moreover, untreated schizophrenic patients
show a reduced energy metabolism in the PFC which has been
related with negative symptoms (Andreasen et al. 1997; Potkin
et al. 2002) yet psychotic symptoms appear associated with
hyperactivity of various cortical areas, including the PFC
(Catafau et al. 1994; Dierks et al. 1999; Shergill et al. 2000).
Classical antipsychotic drugs are thought to alleviate
schizophrenia symptoms by dampening the overactivity of DA
at D2 receptor in ventral striatum. In contrast, second
generation (atypical) antipsychotics preferentially target sero-
tonin (5-HT) receptors such as 5-HT2A, 5-HT2C, and 5-HT1A
receptors (Bymaster et al. 1996; Arnt and Skarsfeldt 1998; Chou
et al. 2003). These receptors are densely expressed in various
subﬁelds of the rat PFC, particularly in its medial aspect
(Pompeiano et al. 1992, 1994). Recent studies have established
their presence in a large proportion of PFC pyramidal and
GABAergic neurons. In particular, 50--60% of the pyramidal
neurons in layers II/III and V of the medial PFC (mPFC) express
5-HT2A and/or 5-HT1A receptors (Amargo ´ s-Bosch et al. 2004;
Santana et al. 2004).
Anatomical and electrophysiological studies have established
the presence of direct afferents from cingulated (Cg),
prelimbic (PL), and infralimbic (IL) areas of the PFC to the
brainstem monoaminergic nuclei, including the dorsal raphe
nucleus (DR) (Aghajanian and Wang 1977; Hajo ´ s et al. 1998;
Sesack et al. 1989; Peyron et al. 1998; Celada et al. 2001) and
the ventral tegmental area (VTA) (Thierry et al. 1979, 1983;
Tong et al. 1996, 1998; Carr and Sesack 2000). These nuclei
give rise to the ascending serotonergic and dopaminergic
innervation of most cortical and limbic brain regions, involved
in numerous physiological functions and in severe psychiatric
conditions such as major depression and schizophrenia
(Carlsson 1988; Jacobs and Azmitia 1992; Weinberger et al.
1994; Williams and Goldman-Rakic 1995; Laruelle et al. 1996;
Robbins 2000; Tzschentke and Schmidt 2000; Schultz 2004).
Previous studies have reported that the systemic adminis-
tration of 5-HT2A receptor ligands such as DOI (5-HT2A/2C
receptor agonist) or M100907 (selective 5-HT2A receptor
antagonist) modulates the DA system (Gobert and Millan
1999; Ichikawa et al. 2001; Minabe et al. 2001; Pehek et al.
2001; Porras et al. 2002), yet the location of the receptors
responsible for these effects was unknown. More recently, it
was reported that the local application of DOI in mPFC
increased burst ﬁring of DA cells in the VTA and the DA output
in the mesocortical DA pathway (Bortolozzi et al. 2005).
Similarly, local DOI application in the mPFC enhanced the
ﬁring rate of DR 5-HT neurons and 5-HT output in rat mPFC
(Martı´n-Ruiz et al. 2001; Amargo ´ s-Bosch et al., 2004). These
observations suggested that the activity of the ascending
cortical DA and 5-HT systems can be modulated by 5-HT2A
receptor activation in pyramidal neurons projecting to mid-
brain.
In the present study, we provide histological support to this
hypothesis by using a combination of tract-tracing techniques
and subsequent in situ hybridization of 5-HT2A receptor mRNA
in PFC sections containing retrogradely labeled neurons
projecting to DR or VTA.
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Animals
Male albino Wistar rats (Iffa Credo, Lyon, France) weighing 250--300 g
were used in this study. Animals were kept in a controlled environment
(12-h light/dark cycle and 22 ± 2  C room temperature) with food and
water provided ad libitum. All experimental procedures used in this
study were in strict compliance with the Spanish legislation and the
European Communities Council Directive on ‘‘Protection of Animals
Used in Experimental and Other Scientiﬁc Purposes’’ of November 24,
1986 (86/609/EEC). Animal work was carried out in the animal
facilities of the School of Medicine of the University of Barcelona and all
protocols used were approved by its Ethical Committee for Animal
Research and by the ‘‘Departament de Medi Ambient i Habitatge’’ from
the Catalan Government (Generalitat de Catalunya).
Animals were deeply anesthetized with sodium pentobarbital (60 mg/
kg ip), and placed in a stereotaxic frame (David Kopf Instruments). Glass
capillary tubes were heated and pulled with a Narishige PE-2 pipette
puller (Narishige Sci. Inst., Tokyo, Japan), Tips were broken to 30 lm
diameter under microscopic control. The micropipettes were then ﬁlled
with a solution of cholera-toxin B subunit (CTB, 2% in distilled water, List
Biological Laboratories, Campbell, CA). CTB was iontophoretically
injected into the DR (AP –7.6 to –7.8; L –3.1 with a vertical 30  angle;
DV –6.2 to –6.8; n = 3) or the VTA (AP –5.6 to –6.0; L –0.5; DV –8.2; n = 3).
Stereotaxic coordinates were taken from the atlas of Paxinos and Watson
(1986). The iontophoretic injections were performed using a 5 lA
positive-pulsed direct current for a total of 5 min (7 s on/off for 10 min).
After surgery, rats were housed individually. Ten days after surgery, the
animals were anesthetized with an ip overdose of sodium pentobarbital
and perfused transcardially with 50 mL of calcium-free Tyrode’s solution
(6.8 g/L NaCl; 0.4 g/L KCl; 0.32 g/L MgCl2 6H2O; 0.10 g/L MgSO4 7H2O;
0.17 g/L NaH2PO4 H2O; 2.2 g/L NaHCO3; 1.1 g/L glucose) containing
0.1% heparin at 37 C, followed by 50 mL of warm (37  C) and 300 mL of
cold (4  C) ﬁxative (4% paraformaldehyde in 0.1 M phosphate buffer, pH
6.9). After perfusion, the skull was opened and the brain carefully
removed and stored for 2 days in a cryoprotective solution (10% sucrose
in 0.1 M phosphate buffer, pH 7.4). The brains were then frozen by slow
immersion into dry-ice chilled isopentane. Tissue sections, 14 lmt h i c k ,
were cut on a microtome-cryostat (Microm HM500 OM, Walldorf,
Germany), and thaw-mounted onto glass slides pretreated with Histogrip
(Zymed Laboratories Inc., San Francisco, CA).
Localization of Injection Sites
Tissue sections taken at the level of the injection sites (VTA or DR) were
incubated during 3--4 days in a humid chamber at 4  Cw i t har a b b i t
antiserum anti-CTB (1:1000; Sigma, St Louis, MI) alone or in combination
with sheep anti-tryptophan hydroxylase (TPH) antiserum (1:100;
Chemicon Intl.) or an anti-tyrosine hydroxylase (TH) monoclonal
antibody (1:1000; Diasorin, Stillwater, MN). Then the sections were
rinsed in 0.1 M phosphate-buffered saline (PBS) and incubated for 30 min
at 37  C with appropriate combinations of the following antisera (1:500,
Molecular Probes, Leiden, NL): AlexaFluor 546-conjugated goat anti-
rabbit (for CTB) and AlexaFluor 488-conjugated goat anti-mouse (for TH)
or AlexaFluor 488-conjugated donkey anti-rabbit (for CTB) and Alexa-
Fluor 546-conjugated donkey anti-goat (for TPH). Finally, the sections
were washed in PBS and coverslipped using Mowiol (Merck, Darmstadt,
Germany). The sections were observed and photographed in an
epiﬂuorescence microscope (Nikon Eclipse E1000, Nikon, Tokyo, Japan).
In Situ Hybridization Histochemistry Procedure
Sections through the PFC from rats injected with CTB were hybridized
with probes against the 5-HT2A receptor mRNA. We used simulta-
neously 3 oligonucleotide probes complementary to bases 128--170,
1380--1427, and 939--987 (GenBank accession no. NM_017254)
(Pritchett et al., 1988). These probes were synthesized on a 380
Applied Biosystem DNA synthesizer (Foster City Biosystem, Foster City,
CA) and puriﬁed on a 20% polyacrylamide/8 M urea preparative
sequencing gel. The oligonucleotides (2 pmol each) were labeled at
their 3#-end with [
33P]a-dATP (>2500 Ci/mmol; Perkin-Elmer, Boston,
MA) using terminal deoxynucleotidyltransferase (Roche Diagnostics
GmbH, Mannheim, Germany), and then puriﬁed by centrifugation using
QIAquick Nucleotide Removal Kit (Qiagen GmbH, Hilden, Germany).
The protocols for in situ hybridization were based on previously
described procedures (Tomiyama et al. 1997). Brieﬂy, frozen tissue
sections were ﬁrst brought to room temperature, ﬁxed for 20 min at 4
 C in 4% paraformaldehyde in Dulbecco’s PBS (13 dPBS: 8 mM
Na2HPO4, 1.4 mM KH2PO4, 136 mM NaCl, 2.6 mM KCl), washed for 5
min in 3x PBS at room temperature, twice for 5 min each in 13 dPBS
and incubated for 2 min at 21  C in a solution of predigested pronase
(Calbiochem, San Diego, CA) at a ﬁnal concentration of 24 U/mL in 50
mM Tris--HCl pH 7.5, 5 mM ethylenediaminetetraacetic acid. The
enzymatic activity was stopped by immersion for 30 s in 2 mg/mL
glycine in 13 dPBS. Tissues were ﬁnally rinsed in 13 dPBS and
dehydrated through a graded series of ethanol. For hybridization, the
labeled probes were diluted in a solution containing 50% formamide,
43 SSC (13 SSC: 150 mM NaCl, 15 mM sodium citrate), 13 Denhardt’s
solution (0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum
albumin), 10% dextran sulfate, 1% sarkosyl, 20 mM phosphate buffer pH
7.0, 250 lg/mL yeast tRNA and 500 lg/mL salmon sperm DNA. Tissue
sections were covered with hybridization solution containing the
labeled probe, overlaid with Nescoﬁlm coverslips (Bando Chemical Ind.,
Kobe, Japan) and incubated overnight at 42  C in humid boxes. Sections
were then washed 4 times (45 min each) in washing buffer (0.6 M NaCl,
10 mM Tris--HCl pH 7.5) at 60  C and once in the same buffer at room
temperature for 30 min.
The speciﬁcity of the hybridization signal obtained with the probes
used has been previously established (Pompeiano et al. 1994). These
controls included the following procedures: 1) the thermal stability of
the hybrids obtained was checked for every probe, 2) for a given
oligonucleotide probe, the hybridization signal was completely blocked
by competition of the labeled probe in the presence of 50-fold excess
of the same unlabeled oligonucleotide, and 3) the distribution of the
hybridization signal at the regional and cellular levels obtained with the
3 probes used independently was identical.
CTB Immunohistochemistry on Hybridized Sections
After the in situ hybridization protocol, tissue sections were kept for 15
min in Tris--HCl buffer (0.10 M pH 7.5) containing 1 M NaCl, 2 mM
MgCl
2 6H2O, and 2% BSA. This buffer was also used in subsequent
incubations and washes unless speciﬁed. The sections were ﬁrst
incubated for 4 h at 37  C with rabbit anti-CTB antiserum (1:1000;
Sigma, St. Louis, MI). Subsequently the sections were washed 3 times (5
min each) and then incubated 30 min with biotinylated goat anti-rabbit
immunoglobulins (1:100, Vector Laboratories). After three 5-min
washes, the sections were incubated for one hour in Vectastain Elite
ABC solution (Vector Laboratories) in a low salt buffer (0.6 M NaCl, 10
mM Tris--HCl pH 7.5). Sections were then washed 3 times and
immersed in a solution of 0.5 mg/mL 3,3#-diaminobenzidine (DAB,
Sigma-Aldrich) in Tris--HCl 0.05 M pH 7.5 containing 1 lL/mL H2O2
until color development (in all cases less than 10 min). The reaction
was stopped by 2 rinses in buffer. CTB staining appeared as brown/
orange precipitate in the soma and proximal dendrites of retrogradely
labeled neurons. The sections were then brieﬂy dipped in 70 and 100%
ethanol, air-dried and dipped into Ilford K5 nuclear emulsion (Ilford,
Mobberly, Cheshire, UK) diluted 1:1 with distilled water. They were
exposed in the dark at 4  C for 6 weeks and were ﬁnally developed in
Kodak D19 (Kodak, Rochester, NY) for 5 min, ﬁxed in Ilford Hypam
ﬁxer (Ilford), washed, and coverslipped using Mowiol (Merck).
Analysis of the Results
Tissue sections processed for in situ hybridization followed by
immunohistochemical detection of CTB were examined in a Nikon
Eclipse E1000 microscope (Nikon, Tokyo, Japan). Cell counting was
performed manually at the microscope with the help of ‘‘analySIS’’
software (Soft Imaging System GmbH, Germany) in 1--3 coronal
sections of each rat corresponding to approximately +3.2 mm from
Bregma, according to atlases of the rat brain (Paxinos and Watson 1986;
Swanson 1999) DAB-labeled cells were considered positive when
a dark precipitate was clearly distinguished from background. Only
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signal (densities of silver grains >3-fold greater than average
background) were considered positive for both markers. Using this
procedure, we cannot discard that the number of 5-HT2A receptor-
bearing neurons has been somehow underestimated. We preferred this
to a false-positive identiﬁcation of 5-HT2A receptor-expressing neurons.
Because the presence of high densities of autoradiographic silver grains
might sometimes mask DAB-labeling, cells in the preparations were
systematically examined at different focal planes to see CTB-immuno-
reactivity at lower planes and hybridization signal at upper planes.
Micrography was performed using a digital camera (Color View 12) and
the software ‘‘analySIS’’ on a Nikon Eclipse E1000 microscope (Nikon)
or an Olympus NewCast microscope (Olympus, NL). Digital images
were treated with Adobe Photoshop (Adobe Software, Mountain View,
CA) to adjust only brightness, contrast and size to make the ﬁnal ﬁgures.
Results
The data reported here correspond to 6 rats in which CTB was
microiontophoretically applied into the VTA or the DR (n = 3
for each site). In all cases, the applied CTB was conﬁned within
the respective nucleus, as shown by the colocalization of the
tracer and the markers for dopaminergic neurons of the VTA
(TH) and serotonergic neurons of the DR (TPH). Figure 1
shows representative ﬂuorescence microscope images illus-
trating the localization of CTB in the VTA (1A--C) and the DR
(1D--F) of 2 of the rats used in the study. Schematic drawings in
Figure 2 illustrate the location of the different microinjections
performed in the VTA and DR.
The application of CTB in the DR or the VTA resulted in the
labeling of pyramidal neurons in layer V and superﬁcial aspect
of layer VI in the mPFC, including the Cg, PL, and IL
subdivisions. CTB-labeled neurons were also found in the
orbitofrontal cortex (OFC). These cells were located mainly in
the ventral OFC of VTA-injected rats whereas they extended
more laterally, reaching the agranular insular cortex in rats
injected with CTB in the DR. Tracer application in the DR
resulted in the labeling of PFC neurons in both hemispheres,
whereas the application in the VTA labeled almost exclusively
neurons in the ipsilateral hemisphere. Figure 3 shows the
schematic location of CTB-retrogradely labeled neurons in the
PFC of 2 rats (V2 and D2 in Tables 1 and 2, respectively)
injected with the tracer in the VTA (V2, Fig. 3A) and in the DR
(D2, Fig. 3B), respectively. Each dot corresponds to 3 CTB-
labeled pyramidal neurons.
Figure 4 shows 5-HT2A receptor mRNA labeling in VTA-
projecting neurons in the mPFC. The presence of the 5-HT2A
receptor mRNA was established by dense clusters of silver
grains, clearly distinguishable from background. As previously
observed (Amargo ´ s-Bosch et al. 2004; Santana et al. 2004), a large
proportion of cells in the Cg, PL, and IL subdivisions of the PFC
were found that contained the 5-HT2A receptor transcript,
mainly in layers II/III and V. No 5-HT2A receptor-positive cells
were found in layer I and a lower abundance of 5-HT2A receptor-
positive cells was observed in layer VI compared with layers III--
V. In occasions, the density of silver grains made difﬁcult the
detection of CTB-immunoreactivity. In these cases, and because
CTB-immunoreactivity and silver grains are localized at different
depths of the tissue preparation, a careful inspection of
individual cells was performed by examining different planes
of the preparation, which contain the CTB signal (lower plane)
and the emulsion for in situ hybridization (upper plane). Table 1
shows the number of CTB-positive cells and the percentage of
double-labeled cells in the mPFC and ventral OFC of the 3 rats
injected with CTB in the VTA. The percentage of CTB-positive
cells that expressed 5-HT2A receptors in the mPFC was rather
high and homogenous (43--60%; 54± 6% on average). Two of the
rats also exhibited a moderate-high (45--65%) percentage of
CTB-positive neurons expressing the 5-HT2A receptor in the
ventral OFC. No unambiguous CTB-positive cells could be
detected in the third animal. It is likely that these individual
differences depend on the size and precise site of injection of
CTB within the VTA. Representative examples of single-labeled
(CTB- or 5-HT2A receptor mRNA positive) and double-labeled
(CTB- and 5-HT2A receptor mRNA positive) cells are shown at
a high magniﬁcation in Figure 4C--E.
A large proportion of CTB-positive pyramidal neurons in the
mPFC and OFC of both hemispheres as labeled by tracer
application in the DR also contained 5-HT2A receptor tran-
scripts (Figs 5, 6 and Table 2). The percentage of CTB-positive
cells that expressed 5-HT2A receptors was also high and
showed little variability in the 3 rats examined. Representative
examples of single-labeled (CTB- or 5-HT2A receptor mRNA
positive) and double-labeled (CTB- and 5-HT2A receptor mRNA
Figure 1. Double immunolabeling showing the localization of CTB injection sites in
the VTA (A) TH (red), (B) CTB (green), and (C) overlay and in the DR (D) TPH (green),
(E) CTB (red), and (F) overlay. The images were taken at the ﬂuorescence microscope
from rats V1 and D1, respectively, and were merged using the software ‘‘analySIS.’’
Scale bar: 100 lm.
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E and 6C--E.
Discussion
The present results indicate that a substantial proportion
(>50% on average) of pyramidal neurons in the PFC projecting
to the midbrain monoaminergic nuclei (DR and/or VTA)
contain the 5-HT2A receptor transcript. These results provide
anatomical evidence for the existence of a PFC-based, 5-HT2A
receptor-mediated distal control of the activity of the
ascending dopaminergic and serotonergic systems. From
a psychopharmacological perspective, the present data suggest
that the interaction of atypical antipsychotics with 5-HT2A
receptors in the PFC may decrease the excitatory PFC input
onto selected neuronal populations within the DR and the VTA
and consequently modulate the activity of the ascending
dopaminergic and serotonergic systems.
Methodological Considerations
5-HT2A receptors are expressed in high densities in PFC (Pazos
et al. 1985; Pompeiano et al. 1994). More recent data using
double in situ hybridization indicate that ~50--60% pyramidal
neurons and ~20--30% GABAergic neurons in layers II--V of the
mPFC contain the 5-HT2A receptor mRNA (Santana et al. 2004).
Our results are consistent with these previous observations and
show the presence of a high number of 5-HT2A receptor
mRNA-expressing cells in the Cg, PL, and IL subdivisions of the
PFC, mainly in layers II--V and a lower abundance in layer VI, as
observed previously (Pompeiano et al. 1994; Amargo ´ s-Bosch
et al. 2004; Santana et al. 2004). This demonstrates that the in
Figure 2. Schematic drawings of coronal sections through the VTA (A) and the DR
(B) illustrate the precise location of CTB injections (shaded areas) in the different rats
used in this study as assessed by CTB immunostaining. Drawings were taken from
Swanson (1999).
Figure 3. Schematic drawings of coronal sections through the PFC illustrating the
localization of CTB-retrogradelly labeled cells after tracer injections in the VTA of rat
V2 (A) and the DR of rat D2 (B). Every dot represents 3 labeled cell bodies. (A) CTB
injections in the VTA only labeled cell bodies in the ipsilateral (i) mPFC (including Cg,
PL, and IL) and medial (ventral) part of the OFC. (B) CTB injections in the DR labeled
cell in the mPFC and OFC of both ipsilateral and contralateral (c) hemispheres.
Drawings were taken from Paxinos and Watson (1986).
Table 1
5-HT2A receptor expression in PFC neurons projecting to VTA
Rat PFC region CTBþ CTBþ/5HT2Aþ % Double-labeled cells
V1 mPFC 24 10 43
OFC (ventral) 21 10 45
V2 mPFC 17 10 59
OFC (ventral) 14 9 65
V3 mPFC 90 54 60
OFC (ventral) 0 0 —
Note: Values are numbers of CTB-positive neurons in each structure (1--2 sections per rat), as
determined by CTB-immunoreactivity (CTBþ). CTB-positive neurons that are also positive for the
5-HT2A receptor transcript (CTBþ/5-HT2Aþ), were identiﬁed by the presence of the 2 markers
(see Methods). Only neurons with unambiguous labeling for both markers were considered
positive, as in the examples shown in Figure 3B.
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expressing cells in the present experimental conditions, that is,
when the hybridization procedure was followed by immunos-
taining of CTB in the same tissue sections. The present
methodology has also been used to determine the presence
of 5-HT4 receptors in PFC neurons projecting to VTA (Pen ˜ as
et al., manuscript in preparation). Recent reports have used
riboprobes in combination with tract tracers (Hur and
Zaborszky 2005; Perez-Manso et al. 2006; Yokota et al. 2007;
Barroso-Chinea et al. 2008). The present study indicates that,
similarly to riboprobes, oligonucleotides can be reliably
combined with tracer immunohistochemistry to identify
proteins expressed in relatively low levels, such as monoamine
receptors, in projection neurons.
CTB-immunoreactive cells were clearly detected in tissue
sections previously treated for in situ hybridization. In the PFC,
these cells were exclusively located in the medial and orbital
divisions. This distribution agrees well with that reported
previously using electrophysiological and tract-tracing methods
for DR- and VTA-projecting neurons (Aghajanian and Wang
1977; Thierry et al. 1979; Thierry et al. 1983; Sesack et al. 1989;
Peyron et al. 1998; Jankowski and Sesack 2004; Gabbott et al.
2005; Geisler and Zahm 2005). One possible limitation of the use
of CTB is the uptake by damaged ﬁbers of passage close to the
application site. This might be a potential confounding factor,
particularly for the identiﬁcation of VTA-projecting neurons,
given the proximity of the VTA to the medial forebrain bundle.
CTB has been reported to be taken up by ﬁbers of passage (Chen
and Aston-Jones 1995). However, this potential limitation can be
minimized by the microiontophoretic application of the tracer,
as used herein. This procedure resulted in a tracer distribution
within the boundaries of the DR and VTA as observed by the
coincidence of the tracer with the TPH and TH immunoreac-
tivity used to label 5-HT and DA neurons, respectively. Non-
speciﬁc uptake by damaged ﬁbers of the medial forebrain bundle
during CTB application in the VTA would have resulted in
labeling of pyramidal neurons in other PFC areas, particularly in
the primary and secondary motor areas, that contain the largest
proportion of corticospinal ﬁbers of all PFC subdivisions
(Gabbott et al. 2005). Such labeling was not observed in any of
the rats, which further supports the speciﬁcity of the labeling
procedure. Only in one rat (D1), CTB labeled a neighboring area
Table 2
5-HT2A receptor expression in PFC neurons projecting to DR
Rat PFC region CTBþ CTBþ/5HT2Aþ % Double-labeled cells
D1 mPFC, ipsilateral
a 12 7 58
OFC, ipsilateral
a 19 13 68
mPFC contralateral
a 19 13 68
OFC contralateral
a 21 18 86
D2 mPFC, ipsilateral 30 20 67
OFC, ipsilateral 38 30 79
mPFC contralateral 23 14 61
OFC contralateral 30 23 77
D3 mPFC, ipsilateral 19 11 58
OFC, ipsilateral 42 26 61
mPFC contralateral 6 4 67
OFC contralateral 27 22 81
Note: Values are the numbers of CTB-positive neurons in each structure (2 sections per rat), as
determined by CTB-immunoreactivity (CTBþ). CTB-positive neurons that are also positive for the
5-HT2A receptor transcript (CTBþ/5HT2Aþ), were identiﬁed by the presence of the 2 markers
(see Methods). Only neurons with unambiguous labeling for both markers were considered
positive, as in the examples shown in Figures 4B and 5B.
aCTB application was aimed at the midline in the DR. However, the micropipette entered the brain
with an angle of 30  to avoid the sinus. Thus, we use the term ipsilateral to refer to the brain
hemisphere where the micropipette ﬁrst entered the midbrain.
Figure 4. Colocalization of 5-HT2A receptor mRNA hybridization signal and CTB-immunoreactivity in the mPFC after injection of the tracer in the VTA. (A) Clusters of
autoradiographic grains corresponding to 5-HT2A receptor mRNA-containing cells are clearly visible in layers II--VI at a low magniﬁcation; the strongest signal is found in layer V
neurons. The boxed area is shown in (B) at a higher magniﬁcation. (B) CTB-immunoreactivity (brown precipitate) can be seen in some cells under the hybridization signal (red--blue
double arrowheads), whereas other cells display only 5-HT2A receptor mRNA signal (blue arrowheads). (C) Detail of a CTB-immunoreactive neuron which lacks the hybridization
signal. (D) Detail of a double-labeled neuron containing CTB-immunoreactivity and a strong 5-HT2A receptor mRNA hybridization signal. (E) Detail of a cell proﬁle showing 5-HT2A
receptor mRNA signal without CTB-immunoreactivity. Bars: 200 lm( A), 30 lm( B), 10 lm( C--E).
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d Va ´zquez-Borsetti et al.Figure 5. Colocalization of 5-HT2A receptor mRNA hybridization signal and CTB-immunoreactivity in the mPFC after injection of the tracer in the DR. (A) Clusters of
autoradiographic grains corresponding to 5-HT2A receptor mRNA-containing cells are clearly visible in layers II--VI at a low magniﬁcation. The boxed area is show in (B) at a higher
magniﬁcation. (B) CTB-immunoreactivity (brown precipitate) can be seen in some cells under the hybridization signal (red--blue double arrowheads) and in cells lacking
hybridization signal (red arrowheads), whereas other cells display only 5-HT2A receptor mRNA signal (blue arrowheads). (C) Detail of a CTB-immunoreactive neuron which lacks
the hybridization signal. (D) Detail of a double-labeled neuron containing CTB-immunoreactivity and a strong 5-HT2A receptor mRNA hybridization signal. (E) Detail of a cell proﬁle
showing 5-HT2A receptor mRNA signal without CTB-immunoreactivity. Bars: 200 lm( A), 30 lm( B), 10 lm( C--E).
Figure 6. Colocalization of 5-HT2A receptor mRNA hybridization signal and CTB-immunoreactivity in the OFC after injection of the tracer in the DR. (A) Clusters of autoradiographic
grains corresponding to 5-HT2A receptor mRNA-containing cells are clearly visible at a low magniﬁcation. The boxed area is show in (B) at a higher magniﬁcation. (B) CTB-
immunoreactivity (brown precipitate) can be seen in some cells under the hybridization signal (red-blue double arrowheads) and in cells lacking hybridization signal (red
arrowheads), whereas other cells display only 5-HT2A receptor mRNA signal (blue arrowheads). (C) Detail of a CTB-immunoreactive neuron which lacks of hybridization signal. (D)
Detail of a double-labeled neuron containing CTB-immunoreactivity and 5-HT2A receptor mRNA hybridization signal. (E) Detail of a cell proﬁle showing 5-HT2A receptor mRNA
signal without CTB-immunoreactivity. Bars: 200 lm( A), 30 lm( B), 10 lm( C--E).
Cerebral Cortex July 2009, V 19 N 7 1683in addition to the DR itself, yet the percentage of double-labeled
cells in the PFC was similar to the rest.
The number of CTB-immunoreactive neurons in the mPFC
was lower when the CTB immunohistochemistry was con-
ducted in sections previously subjected to in situ hybridization
(data not shown). This difference may be attributed to the
previous tissue exposure to the hybridizing conditions and/or
the high salt concentration used in the immunohistochemical
procedure. However, this limitation is unlikely to affect the
conclusions of the present study, because we calculated the
proportion of 5-HT2A receptor mRNA-positive neurons by
reference to the total number of CTB-positive neurons
visualized and not vice versa.
Functional Implications
A large body of data in the literature indicates that the
activation of 5-HT2A receptors by 5-HT results in neuronal
depolarization, reduction of the afterhyperpolarization and
increase of excitatory postsynaptic currents and of the
discharge rate in pyramidal neurons of the PFC (Araneda and
Andrade 1991; Tanaka and North 1993; Aghajanian and Marek
1997, 1999; Amargo ´ s-Bosch et al. 2004; Puig et al. 2005;
Villalobos et al. 2005). 5-HT can also activate 5-HT2A receptors
in GABA interneurons to increase a synaptic GABA input onto
pyramidal neurons (Tanaka and North 1993; Zhou and Hablitz
1999). Hallucinogens such as DOI DOB or LSD also modify
membrane properties of pyramidal neurons and evoke marked
cellular and network changes in PFC in vivo and in vitro
through the activation of 5-HT2A receptors (Aghajanian and
Marek 1997, 1999; Puig et al. 2003; Villalobos et al. 2005;
Gonzalez-Maeso et al. 2007; Lambe and Aghajanian 2007;
Celada et al. 2008).
The present histological data, together with these functional
observations suggest that activation of 5-HT2A receptors in
mPFC pyramidal neurons may increase excitatory inputs onto
DA and 5-HT neurons in the VTA and DR, respectively, as well
as on GABAergic neurons in both nuclei. This is consistent with
the existence of monosynaptic pathways from the PFC to
monoaminergic and GABAergic neurons of the VTA and the DR
(Aghajanian and Wang 1977; Thierry et al. 1979, 1983; Sesack
et al. 1989; Tong et al. 1996, 1998; Hajo ´ s et al. 1998; Peyron
et al. 1998; Celada et al. 2001; Jankowski and Sesack 2004;
Gabbott et al. 2005; Geisler and Zahm 2005). It is also
consistent with the presence of a high density of layer V
pyramidal neurons expressing 5-HT2A receptors (Santana et al.
2004) some of which project to DR and/or VTA, as shown
herein. Hence, the systemic administration of 5-HT2A receptor
agonists/antagonists can distally modulate the activity of the
ascending serotonergic and dopaminergic pathways originated
in the DR and VTA, respectively, via PFC 5-HT2A receptors. In
support of this view is also the fact that local application of the
preferential 5-HT2A receptor agonist DOI in rat mPFC increased
the ﬁring rate of a subpopulation of DR 5-HT neurons,
increased burst ﬁring of DA neurons in the VTA and elevated
the release of both monoamines in PFC (Martı´n-Ruiz et al. 2001;
Bortolozzi et al. 2005). Notwithstanding the existence of this
direct pathway between the PFC and the VTA involving 5-HT2A
receptors, indirect pathways controlling the activity of VTA
neurons cannot be excluded. Thus, the electrical stimulation of
the mPFC evokes monosynaptic excitatory responses as well as
GABAA- and 5-HT1A receptor-mediated inhibitory responses in
DR 5-HT neurons, indicating that most PFC-driven control of 5-
HT neurons occurs via mono- and bisynaptic inputs (Hajo ´ s et al.
1998; Celada et al. 2001; Jankowski and Sesack 2004). However,
this is not the case for DA neurons in the VTA which, in
addition to short monosynaptic excitations consistent with
direct inputs from mPFC (Thierry et al. 1979), show complex
biphasic responses to mPFC stimulation (Tong et al. 1996).
Such biphasic responses might involve alternative pathways
such as: 1) PFC / laterodorsal/pedunculopontine tegmental
nuclei / VTA, and 2) PFC / nucleus accumbens / ventral
pallidum / VTA. These pathways, may also be accountable for
an indirect 5-HT2A receptor-mediated control of DA neurons,
and both have been shown to modulate DA neuron activity via
phasic and tonic inputs, respectively (Floresco et al. 2003).
The present results may have functional implications in
terms of the interaction between both neurotransmitter
systems (e.g., indirect, PFC-mediated vs. direct DR-VTA,
interactions mediated by 5-HT2A receptors in the VTA; Nocjar
et al. 2002). They may also be relevant for the mechanism of
action of atypical antipsychotic drugs. Most agents of this
therapeutic group show greater afﬁnity for 5-HT2A receptors
than for DA D2 receptors and produce a greater occupancy of
cortical 5-HT2 than of subcortical D2 receptors at therapeutic
doses (Nyberg et al. 1998; Meltzer 1999). Clozapine, the
prototypical representative of this group, does not reach—even
at very high doses—the 70% of D2 receptor occupancy,
considered to be the threshold of therapeutic efﬁcacy for
classical antipsychotics (Nordstrom et al. 1998; Kapur et al.
1999; Nyberg et al. 1999). It is unclear how 5-HT2A receptor
blockade may contribute to the therapeutic action of atypical
antipsychotics. Taken together, the present and previous data
suggest that the blockade of 5-HT2A receptors in PFC may
attenuate excitatory inputs from PFC to selected neuronal
groups in the VTA, thus modulating dopaminergic activity.
According to the known connectivity between mPFC and DA
and GABA neurons in the VTA (Carr and Sesack 2000), this
should primarily affect dopaminergic neurons projecting back
to the mPFC and to limbic areas other than the nucleus
accumbens as well as GABA neurons projecting to the latter
nucleus. However, the recent demonstration of marked differ-
ences in the functional properties of mesocortical vs. meso-
limbic DA VTA neurons (Lammel et al. 2008) and the fact that
VTA GABA neurons may indirectly affect DA neuronal activity
make difﬁcult to predict the extent of the 5-HT2A receptor-
mediated excitatory inputs on mesolimbic DA neurons in the
VTA. Indeed, previous evidence from this laboratory indicated
a widespread effect of the local (in mPFC) and systemic
application of DOI in a proportion of VTA DA neurons that
exceeded by and large the low abundance of mesocortical
neurons (Bortolozzi et al. 2005). Also, the fact that DOI
potentiates the amphetamine-induced release of DA in the
nucleus accumbens (Kuroki et al. 2003) accords with the view
that 5-HT2A receptor activation may also affect mesolimbic DA
neurons.
In summary, the combined application of in situ hybridiza-
tion and retrograde tract tracing enabled to show the presence
of 5-HT2A receptor mRNA in pyramidal neurons of the medial
and orbital divisions of the rat PFC that project to mono-
aminergic cell groups of the midbrain. This provides anatomical
support for previous observations indicating a 5-HT2A receptor-
mediated control of DA and 5-HT neurons and raises the
possibility that atypical antipsychotic drugs may partly act by
1684 5-HT2A Receptors in PFC Projections to Monoaminergic Nuclei
d Va ´zquez-Borsetti et al.reducing excitatory PFC inputs onto subcortical structures,
including the midbrain monoaminergic nuclei.
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